Leukemia News and Research

RSS

Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.

EORTC, GIMEMA clinical trial results show high-dose cytarabine improves outcome in AML patients

Results of the EORTC and GIMEMA AML-12 Trial appearing in the Journal of Clinical Oncology show that high-dose cytarabine in induction treatment improves outcome of adult patients with acute myeloid leukemia.

19 Dec 2013

BioLineRx enrolls first patient in BL-7010 Phase 1/2 trial for treatment of celiac disease

BioLineRx, a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today enrollment of the first patient in a Phase 1/2 trial of BL-7010, for the treatment of celiac disease. The first patient was enrolled at Tampere Hospital in Finland, a world-leading site for celiac disease research. Results are expected in mid-2014.

18 Dec 2013

Researchers discover control mechanism that can trigger development of MDS

Researchers at the Moffitt Cancer Center have discovered a control mechanism that can trigger the development of myelodysplastic syndromes (MDS), a group of blood cancers. This finding may lead to therapies capable of preventing the progression of these diseases.

17 Dec 2013

Researchers discover direct evidence of genetic overlap between cognitive ability and schizophrenia

Investigators at The Feinstein Institute for Medical Research have discovered for the first time, direct evidence of a genetic overlap between schizophrenia and general cognitive ability. The findings are published online in Molecular Psychiatry.

17 Dec 2013

Epsilon inks multi-year renewal, expansion agreements with The Leukemia & Lymphoma Society

Epsilon, an Alliance Data company, has signed multi-year renewal and expansion agreements with The Leukemia & Lymphoma Society the world's largest voluntary health agency dedicated to finding cures for blood cancers. Epsilon has partnered with the LLS since the early 1990s, providing marketing services geared toward engaging LLS constituents across a range of fundraising and donor programs such as Light the Night, Team In Training and Man & Women of the Year.

17 Dec 2013

Preclinical data shows BGB324 as potential treatment option for Chronic Myeloid Leukemia

BerGenBio AS, an oncology biopharmaceutical company, announces that preclinical data demonstrating that BGB324 has potential application as a novel treatment for Chronic Myeloid Leukemia, was presented in a poster at the Annual Meeting of the American Society of Hematology, which took place on December 7-10, 2013.

17 Dec 2013

New report shows death rates for lung cancer dropping at a faster pace

The Annual Report to the Nation on the Status of Cancer, covering the period 1975, showed death rates for lung cancer, which accounts for more than one in four cancer deaths, dropping at a faster pace than in previous years. The recent larger drop in lung cancer deaths is likely the result of decreased cigarette smoking prevalence over many years, and is now being reflected in mortality trends. The lung cancer death rate decline, as well as declines in colorectal, breast, and prostate cancer death rates, has also helped drive decreases in death rates for all cancers types combined, a trend that began about 20 years ago.

17 Dec 2013

Scientists continue work to end chemotherapy pain

With this year's $600,000 grant from the Leukemia & Lymphoma Society and $1.5 million grant from the NIH, a Saint Louis University investigator is continuing her work to end chemotherapy pain. Noted pain researcher Daniela Salvemini, Ph.D., is using the funding to capitalize on her recent finding published in Pain, a breakthrough that helps scientists understand a molecular pathway by which pain occurs with certain anti-cancer drugs.

17 Dec 2013

BioLineRx reports promising initial results from Phase 2 trial of BL-8040 in AML patients

BioLineRx, a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today promising initial results for its BL-8040 drug candidate in a Phase 2 clinical trial for patients with relapsed or refractory acute myeloid leukemia (AML).

16 Dec 2013

Dasatinib+letrozole improves survival for women with hormone receptor-positive, HER2-negative metastatic breast cancer

Adding the drug dasatinib to a standard antihormone therapy, letrozole, doubled the time before disease progressed for women with hormone receptor-positive, HER2-negative metastatic breast cancer, according to results of a phase II clinical trial presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14.

13 Dec 2013

Researchers discover completely new targets for treatment of blood cancers

A particularly aggressive form of leukemia is the acute lymphoblastic leukemia (ALL). It is especially common among children and very difficult to treat. Researchers from the University of Veterinary Medicine, Vienna have now discovered completely new targets for the treatment of blood cancers.

13 Dec 2013

Novel ISM strategy enables selection of potentially effective cancer therapies for patients

A new individualized systems medicine strategy, developed at the Institute for Molecular Medicine Finland FIMM and the Helsinki University Central Hospital, enables a selection of potentially effective cancer therapies for individual patients. The promising results achieved by applying this strategy to chemoresistant adult acute myeloid leukemia patients have been recently published in the Cancer Discovery journal.

13 Dec 2013

Combination therapy safe and active in follicular lymphoma

One drug attacks tumor cells directly, the other treats the immune system by taking the brakes off T cell response.

12 Dec 2013

New reports demonstrate the effectiveness of modified T cells in treating blood-borne cancers

At the 2013 American Society of Hematology meeting in Dec. 2013, James Kochenderfer, M.D., investigator in the Experimental Transplantation and Immunology Branch, NCI, presented findings from two clinical trials evaluating the use of genetically modified immune system T cells as cancer therapy.

12 Dec 2013

Late-breaking abstracts on treatment of blood cancers and bleeding disorders presented at ASH meeting

A range of studies highlighting late-breaking research advances in the understanding and treatment of blood cancers and bleeding disorders are being presented today during the 55th American Society of Hematology Annual Meeting and Exposition in New Orleans.

12 Dec 2013

New study may pave way for more effective treatment for deadly childhood cancer

A new study by Canadian researchers may pave the way for more effective treatment of an aggressive and deadly type of brain tumour, known as ETMR/ETANTR. The tumour, which is seen only in children under four, is almost always fatal, despite aggressive treatment. The study proposes a new model for how this brain tumour develops and suggests possible targets to investigate for novel therapies.

12 Dec 2013

New drug combination therapy effective for patients with HER2-positive breast cancer

Combining the chemotherapy drugs docetaxel and carboplatin with the HER2-targeted therapy trastuzumab was identified to be an ideal postsurgery treatment option for patients with HER2-positive breast cancer, regardless of tumor size and whether or not disease has spread to the lymph nodes, according to results from the BETH study presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14.

11 Dec 2013

Celgene subsidiary presents REVLIMID study results on lymphoma at ASH annual meeting

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ:CELG) today announced that results from two studies of REVLIMID (lenalidomide) combinations in patients with diffuse large B-cell lymphoma (DLBCL) were presented at the American Society of Hematology annual meeting in New Orleans, La.

11 Dec 2013

Researchers personalizing cancer treatments for young patients

The aim of personalizing cancer treatments by targeting genomic mutations in the cancer has seen rapid advances in recent years. However, many of these targeted cancer therapies have been more frequently identified for adult patients. Recognizing a need to further explore genomic profiling in pediatric malignancies, the Hugs for Brady Foundation has committed $300,000 to the precision medicine initiative at Rutgers Cancer Institute of New Jersey.

11 Dec 2013

Study shows children with ALL can safely receive intravenous infusions of chemotherapy

Children with acute lymphoblastic leukemia (ALL), the most common form of pediatric cancer, can safely receive intravenous infusions of a reformulated mainstay of chemotherapy that has been delivered via painful intramuscular injection for more than 40 years, research suggests.

11 Dec 2013

Leukemia News and Research

Further Reading

EORTC, GIMEMA clinical trial results show high-dose cytarabine improves outcome in AML patients

BioLineRx enrolls first patient in BL-7010 Phase 1/2 trial for treatment of celiac disease

Researchers discover control mechanism that can trigger development of MDS

Researchers discover direct evidence of genetic overlap between cognitive ability and schizophrenia

Epsilon inks multi-year renewal, expansion agreements with The Leukemia & Lymphoma Society

Preclinical data shows BGB324 as potential treatment option for Chronic Myeloid Leukemia

New report shows death rates for lung cancer dropping at a faster pace

Scientists continue work to end chemotherapy pain

BioLineRx reports promising initial results from Phase 2 trial of BL-8040 in AML patients

Dasatinib+letrozole improves survival for women with hormone receptor-positive, HER2-negative metastatic breast cancer

Researchers discover completely new targets for treatment of blood cancers

Novel ISM strategy enables selection of potentially effective cancer therapies for patients

Combination therapy safe and active in follicular lymphoma

New reports demonstrate the effectiveness of modified T cells in treating blood-borne cancers

Late-breaking abstracts on treatment of blood cancers and bleeding disorders presented at ASH meeting

New study may pave way for more effective treatment for deadly childhood cancer

New drug combination therapy effective for patients with HER2-positive breast cancer

Celgene subsidiary presents REVLIMID study results on lymphoma at ASH annual meeting

Researchers personalizing cancer treatments for young patients

Study shows children with ALL can safely receive intravenous infusions of chemotherapy

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News